

Press release

Andrew Echatti is appointed Chief Executive Officer

Libourne – 14 December 2015 – Fermentalg, an industrial biotechnology company that specializes in the production of oils and proteins derived from microalgae, is pleased to announce a change in governance by separating the functions of Chairman of the Board and CEO. This evolution is reflected in the appointment of Andrew Echatti as its new Chief Executive Officer, Pierre Calleja remain Chairman of the Board of Directors.

Chief Financial Officer for Fermentalg since August 2015, Andrew Echatti has close to 25 years' experience across a range of different sectors. As well as working for Nasdaq-listed US biotechnologies laboratory, Gilead Sciences, for 4 years as Senior Finance Director for Southern Europe, Andrew was General Manager for Sun Microsystems France from 2005 to 2007.

A graduate of the Chicago Booth School of Business with an MBA from Ghent University in Belgium, Andrew Echatti was previously in charge of overseeing the company's financial management and investor relations, and assisting Fermentalg's executive management with the implementation and coordination of scientific, industrial and commercial partnerships. He will now head up all of the company's operations in close collaboration with Chief Scientific Officer, Dr. Hywel Griffiths (PhD).

Pierre Calleja, Founder and Chairman of Fermentalg, said: *“Fermentalg has now reached a level of maturity which merits a change in our organizational structure. With Andrew appointed Chief Executive Officer, I will be focusing on the company's expansion amongst the world's leading biotechnology companies with a very high value-added.”*

Andrew Echatti, Chief Executive Officer, added: *“I would like to thank all of Fermentalg's directors for the trust they have placed in me by appointing me as Chief Executive Officer. The past months have given me a first-hand insight into company's formidable potential and assets in the field of biotechnology. Pierre Calleja has carried out the monumental task of developing our cutting-edge technology for the industrial exploitation of microalgae. Our job now is to take that technology to the market through the precise application of our industrial and commercial strategies. That way, we will be able to create the most value for our company, our employees and our stakeholders.”*

About Fermentalg

Founded in 2009 by Pierre Calleja, Fermentalg is an industrial biotechnology company that specializes in producing sustainable oils and proteins derived from the exceptional properties of microalgae. Its patented technology allows it to target a range of fast-growing global markets, from nutrition and animal feed to cosmetics and health, green chemistry and energy. Fermentalg has already signed its 1st industrial and commercial joint-venture for the production of Omega-3 oils rich in EPA and DHA as well as several other partnerships with leading industrial groups. Fermentalg shares are listed on Euronext in Paris (FR0011271600 - FALG). For more information, visit the Fermentalg website at: www.fermentalg.com.

Press Relations:

ACTUS finance & communication

Alexandra Prisa
Tel: +33 (0)1 53 67 36 90
aprisa@actus.fr

Investor Relations:

ACTUS finance & communication

Jérôme Fabreguettes-Leib
Tel: +33 (0)1 53 67 36 78
jfl@actus.fr